0001678518-22-000002.txt : 20221122
0001678518-22-000002.hdr.sgml : 20221122
20221122121548
ACCESSION NUMBER: 0001678518-22-000002
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20221122
DATE AS OF CHANGE: 20221122
EFFECTIVENESS DATE: 20221122
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lenz Therapeutics, Inc.
CENTRAL INDEX KEY: 0001678518
IRS NUMBER: 901015551
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-380075
FILM NUMBER: 221408990
BUSINESS ADDRESS:
STREET 1: 445 MARINE VIEW AVE., SUITE #320
CITY: DEL MAR
STATE: CA
ZIP: 92014
BUSINESS PHONE: 619-890-5125
MAIL ADDRESS:
STREET 1: 445 MARINE VIEW AVE., SUITE #320
CITY: DEL MAR
STATE: CA
ZIP: 92014
FORMER COMPANY:
FORMER CONFORMED NAME: PRESBYOPIA THERAPIES, INC.
DATE OF NAME CHANGE: 20201030
FORMER COMPANY:
FORMER CONFORMED NAME: PRESBYOPIA THERAPIES, LLC
DATE OF NAME CHANGE: 20160629
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001678518
Lenz Therapeutics, Inc.
445 MARINE VIEW AVE., SUITE #320
DEL MAR
CA
CALIFORNIA
92014
619-890-5125
DELAWARE
Presbyopia Therapies, LLC
PRESBYOPIA THERAPIES, INC.
PRESBYOPIA THERAPIES, LLC
Corporation
true
Evert
Schimmelpennink
c/o Lenz Therapeutics, Inc.
445 Marine View Avenue, Suite 320
Del Mar
CA
CALIFORNIA
92014
Executive Officer
Director
Fred
Guerard
c/o Lenz Therapeutics, Inc.
445 Marine View Avenue, Suite 320
Del Mar
CA
CALIFORNIA
92014
Director
James
McCollum
c/o Lenz Therapeutics, Inc.
445 Marine View Avenue, Suite 320
Del Mar
CA
CALIFORNIA
92014
Director
Clare
Ozawa
c/o Lenz Therapeutics, Inc.
445 Marine View Avenue, Suite 320
Del Mar
CA
CALIFORNIA
92014
Director
Zach
Scheiner
c/o Lenz Therapeutics, Inc.
445 Marine View Avenue, Suite 320
Del Mar
CA
CALIFORNIA
92014
Director
Biotechnology
Decline to Disclose
- 06b
true
0001104659-20-122958
2020-10-30
true
true
true
true
false
0
49002348
49002348
0
Includes $46,999,991.15 new money; $251,192.63 conversion of debt; $1,751,164.25 upon the exercise of warrants
false
45
0
0
0
false
Lenz Therapeutics, Inc.
/s/ Evert Schimmelpennink
Evert Schimmelpennink
President & CEO
2022-11-22